WS Investor
09 Apr 2026, 19:02
Lilly Launches Oral Weight-Loss Drug Foundayo in the U.S.
Eli Lilly and Company announced the U.S. launch of Foundayo (orforglipron), a newly approved oral GLP-1 weight-loss treatment for adults with obesity or overweight conditions.
The once-daily pill, approved by the FDA on April 1, 2026, can be taken without food or water restrictions and is now available via LillyDirect, telehealth providers, and retail pharmacies nationwide. Pricing starts at $149 per month for self-pay patients, with eligible insured users paying as little as $25 monthly.
Clinical trials showed significant weight-loss benefits, with patients losing an average of up to 27 pounds at the highest dose. The drug also demonstrated improvements in cardiovascular risk markers.
Foundayo is the first oral GLP-1 treatment offering flexible dosing without dietary restrictions, marking a notable expansion in the rapidly growing obesity treatment market.
PRNewswire
Eli Lilly and Company announced the U.S. launch of Foundayo (orforglipron), a newly approved oral GLP-1 weight-loss treatment for adults with obesity or overweight conditions.
The once-daily pill, approved by the FDA on April 1, 2026, can be taken without food or water restrictions and is now available via LillyDirect, telehealth providers, and retail pharmacies nationwide. Pricing starts at $149 per month for self-pay patients, with eligible insured users paying as little as $25 monthly.
Clinical trials showed significant weight-loss benefits, with patients losing an average of up to 27 pounds at the highest dose. The drug also demonstrated improvements in cardiovascular risk markers.
Foundayo is the first oral GLP-1 treatment offering flexible dosing without dietary restrictions, marking a notable expansion in the rapidly growing obesity treatment market.
PRNewswire